Janux Therapeutics Reports Third-Quarter 2026 Financial Results
Janux reported financial results for the quarter ended September 30, 2026, and provided a business update.
Story updates
09:02:23 PM UTC
SquawkNews
Janux reported third-quarter 2026 financial results and business updates. It dosed the first patient in a Phase 1 study of JANX013 with JANX007; no financial figures were provided in the release.Material DetailsContext by AI AnalystThis is an early-stage clinical pipeline update alongside quarterly…
09:05:25 PM UTC
SquawkNews
Nov 05 (Reuters) - Janux Therapeutics Q3 collaboration revenue USD 9.289 million.
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended September 30, 2026, and provided a business update.“During the third quarter, we continued to execu…